Ivermectin, an off-patent antiparasitic drug, has shown promise in the treatment of patients with moderate to severe cases of COVID-19, and in some studies have reduced the chance of death by 75 percent, according to a report last week in the Financial Times.
The report said the drug is usually used in the treatment of parasitic infections.
“It’s a generic drug used all over the world,” Andrew Hill, one of the researchers at the University of Liverpool, told the paper. “It costs $0.12 to make the drug substance. The drug costs $3 in India, $960 in the US.”
Harold told the paper the drug seems to make people less infectious when they come down with the virus. He told the paper that vaccination is “central to the response to the pandemic. But this might help reduce infection rates by making people less infectious and it might reduce death rates by treating the viral infection.”
Researchers admit that more studies need to be conducted, and they published their findings in EClinicalMedicine, a clinical journal published by The Lancet. The antiparasitic drug reportedly reduces the replication of the virus inside humans.
“Although our study is small and it is too early to draw conclusions, the trends observed in viral loads, symptom duration, and antibody levels are encouraging and warrant further exploration in larger clinical trials with a higher diversity of patients,” said Carlos Chaccour, Research Professor at Barcelona Institute for Global Health (ISGlobal).
TREND FORECAST: Alternatives to fighting the coronavirus are barely reported in the mainstream media and most often readily dismissed.
As we have pointed out since the COVID War began, rarely, if ever, has the media, politicians, and the anointed “health experts” recommended that people eat healthily, build their immune systems, and consider natural healing remedies.
